Imperva Inc (NASDAQ:IMPV) CRO Michael D. Mooney sold 24,454 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $47.18, for a total value of $1,153,739.72. Following the completion of the sale, the executive now directly owns 24,454 shares in the company, valued at approximately $1,153,739.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of Imperva Inc (NASDAQ IMPV) traded down $0.40 during mid-day trading on Friday, hitting $47.10. The company’s stock had a trading volume of 260,400 shares, compared to its average volume of 384,887. Imperva Inc has a 52 week low of $37.17 and a 52 week high of $52.40. The company has a market cap of $1,615.66, a P/E ratio of 70.37 and a beta of 1.79.
Imperva (NASDAQ:IMPV) last posted its earnings results on Thursday, February 8th. The software maker reported $0.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.13. The business had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.11 million. Imperva had a negative return on equity of 3.37% and a net margin of 7.11%. Imperva’s revenue was up 16.2% on a year-over-year basis. During the same quarter last year, the company earned $0.32 EPS. sell-side analysts anticipate that Imperva Inc will post -0.17 earnings per share for the current fiscal year.
A number of analysts have issued reports on the company. Zacks Investment Research raised Imperva from a “hold” rating to a “strong-buy” rating and set a $53.00 target price on the stock in a report on Friday, February 16th. ValuEngine raised Imperva from a “sell” rating to a “hold” rating in a report on Thursday, February 15th. Imperial Capital raised their target price on Imperva from $50.00 to $55.00 and gave the company an “outperform” rating in a report on Friday, February 9th. Morgan Stanley raised their price objective on Imperva from $37.00 to $39.00 and gave the stock an “underweight” rating in a research report on Friday, February 9th. Finally, Evercore ISI set a $56.00 price objective on Imperva and gave the stock a “buy” rating in a research report on Friday, February 9th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $53.14.
Several institutional investors have recently bought and sold shares of IMPV. SG Americas Securities LLC bought a new position in shares of Imperva during the 3rd quarter worth approximately $134,000. First Quadrant L P CA bought a new position in shares of Imperva during the 3rd quarter worth approximately $136,000. Ameritas Investment Partners Inc. lifted its position in shares of Imperva by 18.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,940 shares of the software maker’s stock worth $141,000 after buying an additional 464 shares during the period. Quadrature Capital Ltd bought a new position in shares of Imperva during the 4th quarter worth approximately $224,000. Finally, Koch Industries Inc. bought a new position in shares of Imperva during the 4th quarter worth approximately $229,000. Institutional investors and hedge funds own 95.91% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Imperva Inc (IMPV) CRO Michael D. Mooney Sells 24,454 Shares” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/23/imperva-inc-impv-cro-michael-d-mooney-sells-24454-shares.html.
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.